Stratos Product Development quietly and abruptly shutters doors

Stratos Product Development of Seattle has abruptly shut down. The design firm had worked with some of the biggest names in tech and healthcare, and its closing leaves other design firms and medtech industry watchers in shock.

E-mailed inquiries to the company returned with this message:  “This response serves to notify you of the closing of our business as of April 28, 2017. Thank you for your patronage and support over the past years of operation. Stratos Product Development wishes to apologize for any inconvenience caused by this closing notification.”

The company was founded in 1987. Microsoft, Apple and Nike can all be counted among its clients. In medtech, the company gained headlines for the work it did to help develop the Proteus Digital Health device.

OncoMed’s demcizumab fails to meet primary endpoint in pancreatic cancer trial

OncoMed Pharmaceuticals’ demcizumab (anti-DLL4, OMP-21M18) has failed to meet its primary endpoint in the Phase 2 YOSEMITE clinical trial in combination with Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin bound) plus gemcitabine in previously untreated metastatic pancreatic cancer patients.

PureTech Health launches new immuno-oncology programme

PureTech Health has launched a new immuno-oncology programme to develop monoclonal antibodies to target newly discovered immunosuppressive mechanisms in pancreatic cancer and other solid tumours.

Single dose of live-attenuated Zika vaccine found to protect mice

New research has revealed that a single dose of the first live-attenuated Zika vaccine has been found to protect mice against the virus.

FDA approves Neurocrine’s Ingrezza to treat tardive dyskinesia

Neurocrine Biosciences has secured approval from the US Food and Drug Administration (FDA) for its Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia (TD).

Scotland approves new drugs for HIV, cancer and others

The Scottish Medicines Consortium (SMC) has approved five new treatments for breast cancer, multiple sclerosis, leukaemia and others.

Takeda, NuBiyota to collaborate on microbiome therapeutics

Takeda Pharmaceutical has partnered with NuBiyota to develop Microbial Ecosystem Therapeutic products for gastroenterology (GI) conditions.

Accenture, BioCelerate partner to advance biopharmaceutical innovation

Accenture and TransCelerate BioPharma’s subsidiary BioCelerate have partnered to advance biopharmaceutical innovation through increased insights in research & development.